
|Articles|July 1, 2020
GlobalData Reports Sales for Big Pharma Companies Have Increased Due to COVID-19
Advertisement
GlobalData, a leading data and analytics company, has found that the COVID-19 pandemic has led to temporarily increased drug sales for big bio/pharma companies in the first quarter (Q1) of 2020. This increase was due to people stockpiling in preparation for limited medical access during the lockdown.
GlobalData’s Pharma Intelligence Center Drug Sales and Forecast Database reveals that global sales in Q1 2020 for companies that were not developing a COVID-19 drug saw an 8% increase in sales when compared to the archived global sales forecast for the same time period. In contrast, companies that were developing a COVID-19 drug only saw a 3% increase.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
2
The New Healthy Aging Imperative and What It Means for Pharma
3
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
4
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
5




